Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can At-Home malaria pills work as well as supervised care?

NCT ID NCT07753967

Disease control Sponsor: Jimma University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This trial compares two ways of taking the standard malaria treatment for Plasmodium vivax: one group receives chloroquine and primaquine under direct medical supervision, while the other takes the same medication at home with phone check-ins. The goal is to see if unsupervised treatment is as effective at clearing the parasite and preventing relapse. About 192 patients with uncomplicated vivax malaria in southwest Ethiopia are taking part. The study tracks cure rates, parasite clearance, and how well patients stick to the 14-day regimen.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Chloroquine and Primaquine combination therapy
What this could lead to
If effective, this could confirm that standard chloroquine-primaquine treatment works against P. vivax malaria in Ethiopia, even when taken at home without supervision.
What could go wrong
The trial is relatively small and observational in nature, and unsupervised adherence may be poor, potentially reducing effectiveness. Results may not apply to other regions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

192 people

The number who actually took part.

Started

Dec 2024

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

1 year and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Eligible patients were those Microscopy-confirmed mono-infection, * Axillary temperature ≥37.5 °C or fever history within 48 hours, * Parasite density \>250 parasites/µl, * Ability to comply with follow-up, * Absence of severe malaria or danger signs, * Nnot pregnant or lactating, * No contraindication to CQ/PQ, * No recent antimalarial use, and * Provision of informed consent. Exclusion Criteria: * Patients didn't fulfilled the inclusion criteria (p.f infection, prior medication, chronic infections,allegy to the CQ-PQ and others)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Malaria vivax are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Plasmodium vivax malaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Malaria vivax

Contacts and locations

Locations

  • Jimma Health Center

    Jimma, Oromiya, 1000, Ethiopia

More trials for these conditions

Other studies related to the condition(s) this trial covers.